Octagon Capital Reduces Stake in Dianthus Therapeutics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 18 2026
0mins
Source: Fool
- Stake Reduction Details: Octagon Capital Advisors reduced its stake in Dianthus Therapeutics by 470,000 shares in Q1 2026, with an estimated trade value of $27.22 million, indicating a cautious outlook on the company's future.
- Remaining Stake Value: Post-sale, the remaining stake in Dianthus is valued at $63.77 million, demonstrating continued confidence in the company's long-term prospects despite the reduction.
- Financial Health: As of March 2026, Dianthus holds approximately $1.2 billion in cash and investments, providing sufficient runway into 2030, which underscores the company's financial stability in the biopharmaceutical sector.
- Clinical Progress: Dianthus achieved an early “GO” decision in its CAPTIVATE trial, confirming 20 responders, highlighting its research potential and competitive edge in the autoimmune space.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DNTH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DNTH
Wall Street analysts forecast DNTH stock price to fall
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 90.860
Low
46.00
Averages
77.00
High
125.00
Current: 90.860
Low
46.00
Averages
77.00
High
125.00
About DNTH
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company engaged in designing and delivering monoclonal antibodies with improved selectivity and potency. The Company is focused on developing complement therapeutics for patients living with severe autoimmune and inflammatory diseases. Its advanced product candidate, DNTH103, is a clinical-stage, highly potent, selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of C1s. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile designed to support less frequent, lower dose, self-administration as a convenient S.C. injection. It is conducting three mid- to late-stage clinical trials with DNTH103 in generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Oorja Bio Secures $30 Million Series A Financing for IPF Therapy
- Funding Support: Oorja Bio announced a $30 million Series A financing from Westlake BioPartners, which will be utilized to advance the clinical development of its first-in-class therapy ORJ-001 for idiopathic pulmonary fibrosis (IPF), marking a significant step forward in the treatment of fibrotic diseases.
- Clinical Trial Plans: ORJ-001 is set to begin Phase 2 clinical trials in 2026, aiming to treat IPF by restoring the function of alveolar epithelial type 2 (AEC2) cells, a novel approach that could fill existing treatment gaps and improve patient quality of life.
- Team Background: The founding team of Oorja Bio comprises biotechnology leaders with extensive experience in drug development and new treatment paradigms, including Sujay Kango and Janethe Pena, who previously led the development of sotatercept at Acceleron Pharma, showcasing strong execution capabilities and industry influence.
- Market Need: Idiopathic pulmonary fibrosis affects over 150,000 adults in the U.S., with current therapies only able to slow disease progression without halting the decline in lung function, thus the successful development of ORJ-001 could provide new hope to meet this significant unmet medical need.
See More
Oorja Bio Secures $30 Million Series A Financing for IPF Therapy
- Funding Support: Oorja Bio announced a $30 million Series A financing from Westlake BioPartners, which will be utilized to advance the clinical development of its first-in-class drug ORJ-001 for idiopathic pulmonary fibrosis (IPF), thereby addressing a significant therapeutic gap in this area.
- Clinical Trial Plans: ORJ-001 is set to begin Phase 2 clinical trials in 2026, aiming to restore the function of alveolar epithelial type 2 (AEC2) cells to promote alveolar repair and reduce inflammatory and fibrotic signaling associated with pulmonary fibrosis, offering new treatment options for patients.
- Team Background: The founding team of Oorja Bio consists of biotechnology leaders with extensive experience in drug development and new treatment paradigms, having previously led the product strategy and clinical development of sotatercept at Acceleron Pharma, showcasing strong execution capabilities and industry influence.
- Market Need: Idiopathic pulmonary fibrosis is a life-threatening disease affecting over 150,000 adults in the U.S., with current therapies only able to slow disease progression without halting the decline in lung function, making the successful development of ORJ-001 potentially transformative for patient outcomes.
See More
Octagon Capital Reduces Stake in Dianthus Therapeutics
- Stake Reduction Details: Octagon Capital Advisors reduced its stake in Dianthus Therapeutics by 470,000 shares in Q1 2026, with an estimated trade value of $27.22 million, indicating a cautious outlook on the company's future.
- Remaining Stake Value: Post-sale, the remaining stake in Dianthus is valued at $63.77 million, demonstrating continued confidence in the company's long-term prospects despite the reduction.
- Financial Health: As of March 2026, Dianthus holds approximately $1.2 billion in cash and investments, providing sufficient runway into 2030, which underscores the company's financial stability in the biopharmaceutical sector.
- Clinical Progress: Dianthus achieved an early “GO” decision in its CAPTIVATE trial, confirming 20 responders, highlighting its research potential and competitive edge in the autoimmune space.
See More
Cormorant Asset Management Acquires Dianthus Therapeutics Shares
- New Investment Position: On May 15, 2026, Cormorant Asset Management disclosed a new position by acquiring 950,000 shares of Dianthus Therapeutics, valued at approximately $55.01 million, indicating strong confidence in the company's future growth prospects.
- Significant Ownership: This acquisition accounts for 4% of Cormorant's reported 13F AUM, highlighting its strategic positioning in the biotechnology sector and commitment to emerging therapeutic innovations.
- Outstanding Stock Performance: As of May 14, 2026, Dianthus shares were priced at $85.34, reflecting a remarkable 350% increase over the past year, significantly outperforming the S&P 500's 25% rise, which underscores the market's recognition of its potential.
- Strong Financial Position: Dianthus ended the quarter with approximately $1.2 billion in cash after raising $719 million earlier this year, providing a projected runway into 2030, which enhances its competitive edge in the biotech industry.
See More
Leads Biolabs Partners with Dianthus to Advance LBL-047 Clinical Development
- Clinical Development Strategy: Leads Biolabs' partner, Dianthus Therapeutics, has prioritized Sjögren's disease, systemic lupus erythematosus, and dermatomyositis for the clinical development of LBL-047, highlighting a commitment to addressing high unmet medical needs and potentially enhancing the company's market position in autoimmune diseases.
- Funding Support: In March 2026, Dianthus completed an upsized public offering, raising approximately $719 million, which provides a robust capital foundation for the global development of LBL-047, thereby strengthening its growth potential in the competitive biopharmaceutical market.
- Clinical Trial Progress: The Phase 1 study of LBL-047 was initiated in December 2025, with top-line results from healthy volunteers expected in the second half of 2026; successful completion of this phase will provide critical data to support further clinical development in prioritized indications.
- Global Partnership Agreement: The exclusive global partnership agreement between Leads Biolabs and Dianthus, with a potential deal value of up to $1 billion, indicates the company's intent to expand in the global market, aiming to maximize the clinical and commercial potential of LBL-047 through collaborative development.
See More
Leads Biolabs Partners with Dianthus to Advance LBL-047 Clinical Development
- Clinical Development Strategy: Leads Biolabs' partner, Dianthus Therapeutics, has prioritized Sjögren's disease, systemic lupus erythematosus, and dermatomyositis for the clinical development of LBL-047, highlighting a commitment to addressing high unmet medical needs, which may enhance the company's market share in autoimmune diseases.
- Funding Support: Dianthus completed an upsized public offering in March 2026, raising approximately $719 million, providing a robust financial foundation for the global development of LBL-047, which is expected to accelerate clinical trial processes and boost investor confidence.
- Clinical Trial Progress: The Phase 1 study of LBL-047 was initiated in December 2025, with top-line results from healthy volunteers anticipated in the second half of 2026, which will provide critical data for subsequent clinical development and further validate its application potential in autoimmune diseases.
- Global Partnership Agreement: The exclusive global partnership agreement between Leads Biolabs and Dianthus, with a potential deal value of up to $1 billion, indicates the company's strategic positioning in the global market, aiming to maximize the clinical and commercial potential of LBL-047 through collaboration.
See More
Oorja Bio Secures $30 Million Series A Financing for IPF Therapy
- Funding Support: Oorja Bio announced a $30 million Series A financing from Westlake BioPartners, which will be utilized to advance the clinical development of its first-in-class therapy ORJ-001 for idiopathic pulmonary fibrosis (IPF), marking a significant step forward in the treatment of fibrotic diseases.
- Clinical Trial Plans: ORJ-001 is set to begin Phase 2 clinical trials in 2026, aiming to treat IPF by restoring the function of alveolar epithelial type 2 (AEC2) cells, a novel approach that could fill existing treatment gaps and improve patient quality of life.
- Team Background: The founding team of Oorja Bio comprises biotechnology leaders with extensive experience in drug development and new treatment paradigms, including Sujay Kango and Janethe Pena, who previously led the development of sotatercept at Acceleron Pharma, showcasing strong execution capabilities and industry influence.
- Market Need: Idiopathic pulmonary fibrosis affects over 150,000 adults in the U.S., with current therapies only able to slow disease progression without halting the decline in lung function, thus the successful development of ORJ-001 could provide new hope to meet this significant unmet medical need.
See More
Oorja Bio Secures $30 Million Series A Financing for IPF Therapy
- Funding Support: Oorja Bio announced a $30 million Series A financing from Westlake BioPartners, which will be utilized to advance the clinical development of its first-in-class drug ORJ-001 for idiopathic pulmonary fibrosis (IPF), thereby addressing a significant therapeutic gap in this area.
- Clinical Trial Plans: ORJ-001 is set to begin Phase 2 clinical trials in 2026, aiming to restore the function of alveolar epithelial type 2 (AEC2) cells to promote alveolar repair and reduce inflammatory and fibrotic signaling associated with pulmonary fibrosis, offering new treatment options for patients.
- Team Background: The founding team of Oorja Bio consists of biotechnology leaders with extensive experience in drug development and new treatment paradigms, having previously led the product strategy and clinical development of sotatercept at Acceleron Pharma, showcasing strong execution capabilities and industry influence.
- Market Need: Idiopathic pulmonary fibrosis is a life-threatening disease affecting over 150,000 adults in the U.S., with current therapies only able to slow disease progression without halting the decline in lung function, making the successful development of ORJ-001 potentially transformative for patient outcomes.
See More
Octagon Capital Reduces Stake in Dianthus Therapeutics
- Stake Reduction Details: Octagon Capital Advisors reduced its stake in Dianthus Therapeutics by 470,000 shares in Q1 2026, with an estimated trade value of $27.22 million, indicating a cautious outlook on the company's future.
- Remaining Stake Value: Post-sale, the remaining stake in Dianthus is valued at $63.77 million, demonstrating continued confidence in the company's long-term prospects despite the reduction.
- Financial Health: As of March 2026, Dianthus holds approximately $1.2 billion in cash and investments, providing sufficient runway into 2030, which underscores the company's financial stability in the biopharmaceutical sector.
- Clinical Progress: Dianthus achieved an early “GO” decision in its CAPTIVATE trial, confirming 20 responders, highlighting its research potential and competitive edge in the autoimmune space.
See More
Cormorant Asset Management Acquires Dianthus Therapeutics Shares
- New Investment Position: On May 15, 2026, Cormorant Asset Management disclosed a new position by acquiring 950,000 shares of Dianthus Therapeutics, valued at approximately $55.01 million, indicating strong confidence in the company's future growth prospects.
- Significant Ownership: This acquisition accounts for 4% of Cormorant's reported 13F AUM, highlighting its strategic positioning in the biotechnology sector and commitment to emerging therapeutic innovations.
- Outstanding Stock Performance: As of May 14, 2026, Dianthus shares were priced at $85.34, reflecting a remarkable 350% increase over the past year, significantly outperforming the S&P 500's 25% rise, which underscores the market's recognition of its potential.
- Strong Financial Position: Dianthus ended the quarter with approximately $1.2 billion in cash after raising $719 million earlier this year, providing a projected runway into 2030, which enhances its competitive edge in the biotech industry.
See More
Leads Biolabs Partners with Dianthus to Advance LBL-047 Clinical Development
- Clinical Development Strategy: Leads Biolabs' partner, Dianthus Therapeutics, has prioritized Sjögren's disease, systemic lupus erythematosus, and dermatomyositis for the clinical development of LBL-047, highlighting a commitment to addressing high unmet medical needs and potentially enhancing the company's market position in autoimmune diseases.
- Funding Support: In March 2026, Dianthus completed an upsized public offering, raising approximately $719 million, which provides a robust capital foundation for the global development of LBL-047, thereby strengthening its growth potential in the competitive biopharmaceutical market.
- Clinical Trial Progress: The Phase 1 study of LBL-047 was initiated in December 2025, with top-line results from healthy volunteers expected in the second half of 2026; successful completion of this phase will provide critical data to support further clinical development in prioritized indications.
- Global Partnership Agreement: The exclusive global partnership agreement between Leads Biolabs and Dianthus, with a potential deal value of up to $1 billion, indicates the company's intent to expand in the global market, aiming to maximize the clinical and commercial potential of LBL-047 through collaborative development.
See More
Leads Biolabs Partners with Dianthus to Advance LBL-047 Clinical Development
- Clinical Development Strategy: Leads Biolabs' partner, Dianthus Therapeutics, has prioritized Sjögren's disease, systemic lupus erythematosus, and dermatomyositis for the clinical development of LBL-047, highlighting a commitment to addressing high unmet medical needs, which may enhance the company's market share in autoimmune diseases.
- Funding Support: Dianthus completed an upsized public offering in March 2026, raising approximately $719 million, providing a robust financial foundation for the global development of LBL-047, which is expected to accelerate clinical trial processes and boost investor confidence.
- Clinical Trial Progress: The Phase 1 study of LBL-047 was initiated in December 2025, with top-line results from healthy volunteers anticipated in the second half of 2026, which will provide critical data for subsequent clinical development and further validate its application potential in autoimmune diseases.
- Global Partnership Agreement: The exclusive global partnership agreement between Leads Biolabs and Dianthus, with a potential deal value of up to $1 billion, indicates the company's strategic positioning in the global market, aiming to maximize the clinical and commercial potential of LBL-047 through collaboration.
See More
